Did the company provide any guidance for Q3 2025 or full-year 2025, and how does it stack up against consensus forecasts?

Guidance?

In the August 14, 2025 release Nuwellis, Inc. (NASDAQ: NUWE) only disclosed its Q2 2025 results and a general business update. The filing does not contain any forward‑looking guidance for either the upcoming third quarter of 2025 or the full‑year 2025 outlook.

Implication vs. consensus

Because the company offered no explicit Q3 or FY 2025 targets, analysts and the market are left to rely on existing consensus estimates (e.g., revenue, EPS, and cash‑burn forecasts compiled by Bloomberg, FactSet, or Refinitiv). In the absence of company‑issued guidance, the consensus remains the primary benchmark. This information gap can be interpreted in a few ways:

• Neutral‑to‑negative sentiment: Historically, a failure to provide guidance—especially when peers are doing so—creates uncertainty and can pressure the stock lower as investors price in a “cautionary” signal.
• Technical angle: Nuwellis has been trading in a tight range around its recent 52‑week low. The lack of forward guidance removes a catalyst that could have sparked a breakout; a breach above the recent high (≈ $4.20) on strong volume would be a bullish technical signal, while a break below the $3.50 support could trigger further downside.
• Actionable view: Until the company issues a Q3 or FY 2025 outlook, the prudent trade‑‑setup is to stay on the sidelines or position modestly with a short‑bias, targeting the $3.50 support level. If the stock rallies on any unexpected positive news (e.g., a new product launch or partnership) that hints at stronger‑than‑expected performance, a short‑cover could accelerate a move toward the $4.20 resistance. Conversely, a continued lack of guidance combined with any softening in the broader med‑tech sector may push the price toward the $3.20‑$3.30 floor.